Cell & Gene therapy
April 20, 2023
What is autologous?
The term "autologous" is most frequently found in the context of cell therapy. In this article, we will therefore take a closer look at this revolutionary therapeutic approach.
April 19, 2023
What is allogeneic?
What does "allogeneic" mean, precisely? How do allogeneic cell therapies work, and what is the difference to autologous approaches? Questions like these will be answered in this article.
October 11, 2022
Viral vectors for gene therapy: What to expect in 2023
Viral vectors are looking ahead a bright future in gene therapies. In this article, we give you an overview of the most frequently used viral vectors and have a glimpse at their possible future applications.
October 10, 2022
Small batch manufacturing & fill-finish in cell and gene therapy
A great example is the treatment of insidious cancers with CAR T-cells, that relies on modifying the patient’s own T-cells to instill them with a targeted way to fight cancer cells. Learn more why forming strong collaborations will solve many issues!
August 9, 2022
Simplifying Cryopreservation of Cell Monolayers
Advanced cell-based assay workflow with CryoLogyx Thaw and Test pre-plated cell and controlled, scalable freezing process solution RoSS.pFTU to achieve effective cryopreservation of cells.
July 4, 2022
AAV production workflow – where do we come in?
The production of AAVs requires to fulfill high standards and is thus in need of state of the art technologies. Find out what the key elements in the production of AAVs are and how our products help to carry them out.
July 4, 2022
Safe handling of AAVs
Adeno-associated viruses are an increasingly important tool in biopharma, used for example as vectors for gene therapy and vaccines. But how are they adequately – and safely – handled? Here are some key aspects to consider along their supply chain.
June 23, 2022
CAR-T manufacturing process and the supply chain behind it
Mastering the complex CAR T manufacturing process and the associated supply chain challenges in the cell and gene area are the major bottlenecks during the large-scale commercialization of highly promising CAR T cell products.
June 9, 2022
Gene therapy manufacturing - 5 requirements to scale up
Gene therapies have become a highly promising field of groundbreaking next generation treatment, but there are some challenges to face within the manufacturing process. Here are 5 factors that will be crucial for upscaling gene therapy manufacturing with single-use technology.
March 28, 2022
Costs for CAR T-cell therapy - How to deploy cost-efficiency
CAR T-cell treatments are deservedly on the rise, as the effectiveness of CAR T-cell products for formerly hard to treat hematology malignancies has been established in clinical trials. This article will highlight one of the less discussed issues of immunotherapy in cancer treatment: it’s current price tag could hamper the broad accessibility to patients.
February 15, 2022
Whitepaper: How controlled freezing enables scalability
In a comprehensive study the impact of ice front growth speed on scalability of freezing protein solutions has been evaluated.
January 10, 2022
Safety & Speed: handling two major factors in CAR T-cell therapy
In order to allow for a smooth and functioning process, a reliable supply chain, tailored to the specific needs of autologous therapies, is a prerequisite. Single Use Support has developed an end-to-end process solution for cell and gene therapies.